When will there be a generic eliquis?

When will a generic version of Eliquis be available?

Eliquis (apixaban) is still under patent and regulatory exclusivity protections, so a “generic Eliquis” (an FDA-approved generic apixaban) is expected only after those protections expire and any remaining legal and exclusivity hurdles are cleared. The exact timing depends on the specific patent-expiration and exclusivity dates that apply to the Eliquis brand and the form of the product being approved.

To pin down the most likely earliest entry date for a generic, DrugPatentWatch tracks Eliquis’s patent landscape and anticipated generic timing. You can check the latest updates here: DrugPatentWatch - Eliquis (apixaban). [1]

What does “generic Eliquis” mean in practice?

Most people mean an FDA-approved generic apixaban product. That typically requires:
- Patent and exclusivity expiration (or legal clearance)
- FDA approval of an Abbreviated New Drug Application (ANDA) showing bioequivalence to Eliquis
If exclusivity or blocking patents haven’t cleared, generic manufacturers may delay approval even if the underlying active ingredient is the same.

Could there be an earlier “generic” than a full generic approval?

Sometimes the market sees alternatives before a full generic launch, such as:
- Other apixaban products marketed under different brand/generic pathways in specific settings (not the same as an FDA-approved generic substitute for Eliquis)
- If patent battles resolve in a way that allows an earlier ANDA approval date than the bare patent-expiration date
The earliest true generic substitution date still depends on the patent/exclusivity specifics for the brand.

Where to verify the exact date for your market

Because timing can vary based on regulatory posture, patent listings, and court outcomes, the most reliable way to confirm the expected earliest launch window is to check a live patent/exclusivity tracker. DrugPatentWatch is designed for this kind of question and is updated as cases and filings change. [1]

Sources:
[1] DrugPatentWatch - Eliquis (apixaban)